Live -Webinar 2014 - The QSR (21 CFR 820): What each subpart really requires
Topics/Call fo Papers
DESCRIPTION
The QSR regulations - with the exception of 820.30 Design Controls - have not changed significantly over the last several decades. However, the interpretation of each subpart has been shaped and updated with new FDA insight into critical quality processes. Learn about key FDA focus areas in each subpart, how to prevent the most common 483 and warning letter observations and how to establish a lean compliance system within your company. Get tips from an expert in remediation who has helped Fortune 500 medical device companies through risk management, design control, DHF and process validation remediation activities.
Why should you attend :
The QSR is examined and practical advice is discussed using case studies, 483 and warning letter text and a practical approach to implementing quality improvements and alignment to FDA quality system requirements.
Areas Covered in the Session:
21 CFR 820 (Subpart A - Subpart O)
Who will benefit: (Titles)
Engineers
Vice Presidents
Directors
Quality Professionals
Compliance Staff and Officers
Consultants
CEOs
Anyone Interested in the Topic
Webinar Includes:
Q/A Session with the Expert to ask your question
PDF print only copy of PowerPoint slides
60 Minutes Live Presentation
Certificate
The QSR regulations - with the exception of 820.30 Design Controls - have not changed significantly over the last several decades. However, the interpretation of each subpart has been shaped and updated with new FDA insight into critical quality processes. Learn about key FDA focus areas in each subpart, how to prevent the most common 483 and warning letter observations and how to establish a lean compliance system within your company. Get tips from an expert in remediation who has helped Fortune 500 medical device companies through risk management, design control, DHF and process validation remediation activities.
Why should you attend :
The QSR is examined and practical advice is discussed using case studies, 483 and warning letter text and a practical approach to implementing quality improvements and alignment to FDA quality system requirements.
Areas Covered in the Session:
21 CFR 820 (Subpart A - Subpart O)
Who will benefit: (Titles)
Engineers
Vice Presidents
Directors
Quality Professionals
Compliance Staff and Officers
Consultants
CEOs
Anyone Interested in the Topic
Webinar Includes:
Q/A Session with the Expert to ask your question
PDF print only copy of PowerPoint slides
60 Minutes Live Presentation
Certificate
Other CFPs
- Design Inputs - Design Outputs Traceability Matrix - Principles of Lean Documents and Lean Configuration
- Internet Issues for FDA-Regulated Industry ? A Review of Issues Involving Social Media
- Bioterrorism and Food Security-A Cultural Conundrum
- Best Practices for Quality Risk Management for Pharmaceutical Industry
- US, EU and Japan GMP Requirements: Practical ICH Area Differences, Healthcare Authority Inspection Focus
Last modified: 2014-11-01 14:00:54